Home Shennuo Medical's First-Ever Domestic Peripheral Nerve Stimulation System Receives Market Approval

Shennuo Medical's First-Ever Domestic Peripheral Nerve Stimulation System Receives Market Approval

Apr 20, 2026 18:03 CST Updated 18:03
SNEURO MEDICAL

Developer and Manufacturer of Implantable Neurostimulation and Brain-Computer Interface Products

MicroCyto

Synthetic Biology Technology Developer

IRIS

Contact Lens Provider

Edge Medical

Developer of Robot-Assisted Minimally Invasive Surgical Systems

Click AboveBlue TextFollow Us

Image
Image

Recently, the first domestically-produced peripheral nerve stimulation system (PNS) in China, independently developed by SNEURO MEDICAL (Hangzhou Shenluo Medical Technology Co., Ltd.), has been approved for marketing. The system includes a peripheral nerve stimulation electrode (NMPA approval No. 20263120750), a peripheral nerve stimulator (Zhejiang NMPA approval No. 20262120207), and a peripheral nerve stimulator programmer (Zhejiang NMPA approval No. 20262120208). This marks a milestone breakthrough, filling the product gap in this field within China.

Bo Yuan exclusively led the A-round financing of SNEURO MEDICAL in 2021 and participated in the B-round, B+-round, and C-round financings in 2022, 2024, and 2026, respectively.

Image


1. Redefining Neuromodulation: Technological Innovation in Treatment, Clinical Evidence in Efficacy

SNEURO MEDICAL has transformed neuro-modulation therapy from traditional "major surgery" to minimally invasive "outpatient procedures" through multiple proprietary patented designs, making treatment more accessible:

Puncture Implantation: Ultrasound-guided puncture implantation can be completed in an outpatient setting.

Ultra-Long Cycle Treatment: Up to 30 Days of Treatment.

Suture-Free Design: Unique suture-free design, no suturing required for the implant wound, avoiding secondary harm to the patient.

Anti-fall Design: Unique anti-displacement design prevents electrode displacement, ensuring continuous and effective treatment.

2. Excellent Efficacy: Based on High-Level Evidence

The prospective, multicenter, randomized controlled clinical trial of SNEURO MEDICAL's peripheral nerve stimulation system fully demonstrated its excellent safety and efficacy. The effective rate of pain relief ≥50% reached 96.00%, and indicators such as depression scores and quality of life impact showed significant improvement from baseline.


Image

Previous Recommendations

Boyu Partners News | MicroCyto Completes 300 Million Yuan A+ Round Financing, Collaborates with Stanford University to Launch AI Bio-Computing Open Platform PoseX at ICLR 2026

Image

Boyun Partner News | IRIS Completes Over 100 Million Yuan in B+ Round Financing, Reshaping Contact Lens Manufacturing with New Productive Forces

Image

Boyu Partners News | Edge Medical's "Three-in-One" Surgical Robot Platform Receives NMPA Approval

Image